Fig. 3

PI3K, Akt, or PKCβ inhibitor suppressed the rosiglitazone-induced endothelial cell migration and permeability. a HUVECs were treated with rosiglitazone (10 μM) with or without PI3K inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM) simultaneously. Representative micrographs at × 400 magnification. b The numbers of cells that moved were counted. Data are represented as % of control. c HUVECs were treated with rosiglitazone (10 μM) with or without PI3K inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM) simultaneously. The leakage of EB bounded to albumin from the upper to lower chamber was measured. Data are represented as % of control. (n = 4; * p < 0.01 compared with control, † p < 0.01 compared with wells treated with rosiglitazone only)